Abstract: The C1 esterase inhibitor (C1-INH) from human plasma is a sialic-acid-containing glycoprotein which can bind other glycoproteins and glycolipids which may be components or even membrane components of microoganisms of viral and bacterial origin. In accordance with the invention, this binding can inhibit the penetration of certain viruses into target cells.

Abstract: A description is given of a one-component tissue adhesive containing, in aqueous solution, fibrinogen, F XIII, a thrombin inhibitor, prothrombin factors, calcium ions and, where appropriate, a plasmin inhibitor and of a process for the production thereof. This adhesive can be reconstituted from a freeze-dried form with water. It can contain aLL active substances in pasteurized form and is then free of the risk of transmission of hepatitis and HTLV III.

Abstract: The present invention relates to a process for the preparation of a product of blood coagulation factors II, VII, IX and X which is virtually free of virus, the process comprising heating an aqueous liquid containing these factors in the presence of calcium ions and a chelating agent and, optionally, an amino acid, a saccharide or sugar alcohol, antithrombin III and/or heparin. The product can be used for the treatment of blood coagulation disorders.

Abstract: A process for the preparation of a concentrate of von Willebrand factor is described, entailing a solution of a complex of this factor with factor VIII:C being optionally pasteurized and treated with an anion exchanger, there being no binding of the von Willebrand factor.

Abstract: A method for the determination of soluble fibrin in a body fluid of a species is described, entailing use of a binding partner which is bound to a solid phase, and of a labeled bioaffinity binding partner, for fibrin.

Abstract: A description is given of the possibility of using transglutaminases in a process for the preparation of an immunosuppressant. Additionally described is a pharmaceutical containing a transglutaminase and a plasminogen activator inhibitor.

Abstract: The disclosed invention provides a method for determining the plasminogen activator (PA) activity in a biological fluid. The method involves the use of proteolytically-degraded plasminogen and effectively eliminates the influence of alpha-2-antiplasmin on the determination of PA activity.

Abstract: A method and an agent for the functional determination of protein C inhibitor in body fluids are described, in which this fluid is incubated with a known amount of a plasminogen activator, fibrinogen and a sulfated carbohydrate, and the residual activity of the plasminogen activator is determined, and from this the amount of protein C inhibitor is determined.

Abstract: A description is given of the possibility of using transglutaminases in a process for the preparation of an immunosuppressant.Additionally described is a pharmaceutical containing a transglutaminase and a plasminogen activator inhibitor.

Abstract: A process for the preparation of a pasteurized factor VIII concentrate with high specific activity and stability is described, which comprises adsorbing impurities from the solution containing the factor VIII by at least two-fold adsorption with Al(OH).sub.3, an anion exchanger or Ca.sub.3 (PO.sub.4).sub.2, preferably with two different adsorbents from this group.

Abstract: A description is given of a one-component tissue adhesive containing, in aqueous solution, fibrinogen, F XIII, a thrombin inhibitor, prothrombin factors, calcium ions and, where appropriate, a plasmin inhibitor and of a process for the production thereof.This adhesive can be reconstituted from a freeze-dried form with water. It can contain all active substances in pasteurized form and is then free of the risk of transmission of hepatitis and HTLV III.

Abstract: A process for the purification of plasminogen activator inhibitor 2 (PAI-2) including the steps of preincubating a PAI-2-containing solution with a compound which cleaves disulfide linkages, mixing the solution with a water-soluble acridine or quinoline base to precipitate impurities in the solution, and separating the precipitated impurities to obtain PAI-2 in purified form.

Abstract: A process for removing toxins from solutions of proteins, in which an aqueous solution of a protein which contains a buffer substance, a chelating agent and a detergent is subjected to an ion exchange chromatography, is described.

Abstract: An agent for the therapy of hemophilia A which is resistant to treatment with factor VIII is described, and is obtainable by maintaining a mixture of factor VIII, antithrombin III, a phospholipid and calcium ions in an aqueous solution at a temperature of from 1.degree. to 45.degree. C. for at least one minute, adding factor IX, and maintaining the solution at a temperature offrom 1.degree. to 45.degree. C. until addition of a sample of this solution to an inhibitor plasma results in a partial thromboplastin time (PTT) of 15 to 30 seconds, where appropriate adding a polyol and, where appropriate, an amino acid, and, where appropriate, drying the solution.

Abstract: The invention relates to a method for the determination of the activity of serine proteases and serine protease inhibitors in plasma or other biological fluids.The only methods hitherto available for rapid and accurate determination of the content of serine proteases or serine protease inhibitors have been very time-consuming and methodologically demanding. In the method according to the invention for the determination of the activity of serine proteases or serine protease inhibitors, specific inhibitors are inactivated by addition of at least one oxidizing agent and, where appropriate, at least one detergent. The addition of an omega-aminocarboxylic acid enhances and observed effects when the serine protease is plasmin.

Abstract: Insulin derivatives of the general formulae I and IIX--(Y.sub.1 --S--S--Y.sub.2 --Z--"Insulin").sub.m IA--S--Y.sub.3 --Z--"Insulin" IIin whichX is a radical of a physiologically tolerated carbon compound,Y.sub.1, Y.sub.2 and Y.sub.3 are, independently of one another, a chemical bond or an organic chemical bridge,S is a sulfur atom,"Insulin" denotes the biologically active peptidic portion of a natural, semisynthetic or synthetic insulin or an insulin which has been prepared by genetic engineering, or one of its biologically active analogs without the inessential amino group,Z is an amino group which is inessential for the biological activity of insulin,A is a hydrogen atom or the radical of a mercapto-containing, physiologically tolerated hydrocarbon compound, andm is an integer from 1 to 20,agents containing these derivatives, a process for the preparation of these derivatives, and their use for the treatment of metabolic disorders, are described.

Abstract: A process for the production of a preparation of blood coagulation factor VIII which makes it possible to obtain a pasteurized product which is virtually free of immunoglobulins, isoagglutinins, fibronectin and coagulable fibrinogen is described.A product of this type can be used for the treatment of blood coagulation disturbances.

Abstract: A process for the preparation of a factor VIII:C-deficient plasma is made available, in which a starting plasma is consecutively treated with antibodies against von Willebrand factor and antibodies against factor VIII:Ag. The deficient plasma prepared in this way contains less than 0.5% residual activity of factor VIII:C.

Abstract: A pasteurized human firbinogen which can be used therapeutically, and a process for its preparation are described.

Abstract: The invention relates to a process for the preparation of C1 inactivator, which, if appropriate, is hepatitis-free and, if appropriate, can be lyophilized, and its use as a medicament.